Anthracycline Cardiotoxicity: From Bench to Bedside
Population
Patients receiving anthracyclines and preclinical models of anthracycline cardiotoxicity
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Highlights ongoing monitoring challenges in anthracycline-treated patients; leaves open optimal prevention strategies for prospective trials.
Key Points
- The aim is to understand the mechanisms behind anthracycline-induced cardiotoxicity and identify improvements needed for safer cancer therapies.
- Review of discussions from the First International Workshop on Anthracycline Cardiotoxicity (2006)
- Incorporation of preclinical and clinical perspectives on anthracycline cardiotoxicity
- Pathogenic mechanisms of cardiotoxicity are still not fully understood despite extensive research.
- New drugs and therapies often increase the risk of cardiotoxic effects from anthracyclines.
Structured PICO
P
Population
Patients receiving anthracyclines and preclinical models of anthracycline cardiotoxicity
I
Intervention
Anthracyclines
O
Outcome
Cardiotoxicitysafety
This review provides a comprehensive overview of the preclinical mechanisms and clinical challenges of anthracycline-induced cardiotoxicity.
Cite This Study
Gianni et al. (2008) studied this question.